A landmark scientific study led by researchers at Oregon Health & Science University (OHSU) has delivered the first large-scale, real-world evidence evaluating OHSU psilocybin study outcomes. Published in JAMA Network Open, the study tracked hundreds of adults receiving guided sessions across licensed service centers throughout the state. The findings reveal that state-regulated psilocybin experiences lead to substantial, sustained reductions in depression, anxiety, and post-traumatic stress disorder (PTSD) symptoms, while maintaining a strong safety record.
While previous clinical trials evaluated psilocybin primarily in strict laboratory environments, this research provides vital real-world data from Oregon’s first-in-the-nation legal framework. As interest in non-traditional wellness grows, these findings offer empirical proof of how regulated, facilitated care operates outside academic research settings.
Real-world data on anxiety, depression, and PTSD relief
The study evaluated a cohort of 346 adults who participated in single supervised psilocybin sessions between November 2024 and March 2026 across 24 licensed service centers in Oregon, with follow-up assessments tracked through June 2026. Services were delivered under the care of state-licensed facilitators. Participants completed psychological evaluations prior to their sessions and were re-evaluated at one week, one month, and three months post-session.
When analyzing the specific OHSU psilocybin study outcomes at the three-month follow-up mark, researchers observed significant mental health improvements across the participant cohort:
- Depression and anxiety reductions: Participants reported marked decreases in moderate-to-severe symptoms of depression and anxiety compared to their baseline levels.
- PTSD symptom relief: Individuals experiencing post-traumatic stress symptoms saw clinically meaningful improvements in symptom severity.
- Overall mental well-being: In addition to symptom reduction, participants measured higher scores in overall life satisfaction and psychological well-being.
Notably, these positive outcomes occurred across a broad cross-section of adults, including individuals who did not explicitly seek out services to treat a diagnosed mental health condition.
High participant satisfaction and personal meaning
Beyond symptom tracking, the research team evaluated how participants subjectively perceived the value of their guided sessions. The long-term retention rate remained remarkably high, with over 90% of participants completing assessments through the three-month mark.
Key findings regarding participant satisfaction include:
- Immediate perceived benefit: At one month following their psilocybin administration session, 91.5% of participants reported that they directly benefited from the experience.
- Profound personal significance: Nearly two-thirds of participants (64.9%) described their guided psilocybin journey as being among the ten most meaningful experiences of their entire lives.
- Sustained life satisfaction: The psychological insights gained during sessions translated into lasting improvements in self-reported daily functioning and emotional stability months after the session concluded.
If you’re interested in the therapeutic use of psilocybin, book a call with Omnia to learn more about our individual sessions in Oregon.
Safety profile and low risk in state-regulated centers
Safety has remained a paramount question for health professionals, policymakers, and prospective clients considering psilocybin care. The OHSU research team examined safety data closely and concluded that serious adverse reactions were rare within Oregon’s regulated infrastructure.
The study highlighted key safety metrics:
- No serious physical events: Zero participants experienced serious physical health complications related to their psilocybin session.
- Low rate of behavioral adverse events: Only four participants (1.2% of the total cohort) experienced acute behavioral distress requiring medical attention. Significantly, all four individuals were psychedelic-naive, meaning it was their first time consuming psilocybin.
- Minimal reported harm: At the three-month evaluation, only 2.3% of participants (7 individuals) felt their overall experience was harmful, underscoring that Oregon’s mandatory screening, facilitator training, and laboratory testing protocols provide an effective safety net.
You might be interested in: Unlocking the benefits of psilocybin mushrooms: A guide
Why this research matters for psychedelic policy
Passed by Oregon voters via Measure 109 in 2020 and launched in 2023, Oregon’s framework created a non-medical, state-regulated model for adult access. With over 20,000 individuals having accessed licensed service centers to date, evaluating the program’s real-world impact is crucial for state leaders and public health authorities.
By establishing that facilitated psilocybin care can be delivered safely and effectively in commercial service centers, these OHSU psilocybin study outcomes offer a scientific blueprint for other jurisdictions. States currently developing or evaluating similar regulated models can look to this data as evidence that regulated, non-prescription access yields outcomes comparable to rigorous academic trials.
For complete details on the study design, methodology, and reported outcomes, you can read the original news coverage directly on KOIN News.
Experience safe & supported psilocybin therapy. Consult Omnia Group today.